CME: Best practice in the systemic treatment of advanced and recurrent endometrial cancer
ACCREDITATION EXPIRED: August 25, 2024
Activity Description / Statement of Need:
In this online, self-learning activity:
Endometrial cancer is the most common gynecologic cancer and the fourth most common cancer in women living in the United States, with approximately 66,000 cancers of the uterine corpus diagnosed every year and over 12,000 associated deaths. The vast majority of women are diagnosed with endometrial cancer after the age of 50, and risk factors are obesity, level of physical activity, increasing age, and the presence of a variety of comorbid, chronic health conditions. The costs associated with endometrial cancer may amount to tens of thousands of dollars per patient, depending on the stage of disease upon diagnosis. The five-year survival rate for patients with localized disease is 95%, but survival rates drop to 18% in patients with advanced disease, one in ten patients is diagnosed with distant cancer, representing an area of ongoing clinical need.
Target Audience:
HCPs including: medical, including gynecologic, oncologists; physician assistants, nurse practitioners, and pharmacists who practice in oncology; and other clinicians who commonly encounter patients with advanced or recurrent endometrial cancer.
Commercial Support Disclosure: This program is supported by an educational grant from Merck.
This activity is free of charge.
Release Date: August 25, 2023 -- Expiration Date: August 25, 2024
Faculty: Dario Roque, MD
Agenda
|
Faculty introduction, disclosures |
|
Introductory content and review of advanced endometrial cancer
|
|
Treatment considerations for advanced and recurrent endometrial cancer, including guideline-based approaches and clinical trial evidence
|
|
Summary, conclusions, and best practice recap |
Learning Objectives
By the end of the session the participant will be able to:
- Recall challenges and barriers to care associated with the treatment of patients with advanced and recurrent endometrial cancer.
- Describe present and emerging therapy for advanced and recurrent endometrial cancer, including biomarker-directed treatment.
- Design a treatment plan for a patient with advanced and recurrent endometrial cancer.
Accreditation
ACCME Activity #202547898
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
Faculty Disclosure and Resolution of COI
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.
Disclosure of Faculty: Dario R. Roque, MD, Assistant Professor, Gynecologic Oncology, Feinberg School of Medicine at Northwestern, has received financial compensation from Myriad and GSK for consulting and/or speaker's bureau work, in addition to serving as a surgical proctor for Intuitive Surgical.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.
Faculty WILL NOT discuss off-label uses.
All relevant financial relationships have been mitigated.
ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Instructions
- Read the learning objectives above
- Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
- View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
- Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
- Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.
System Requirements
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Additional Courses That Are Related To This Activity
Contemporary treatment approaches in the management of graft-versus-host disease (GVHD)
Myeloma bone disease: Monitoring and management
Prediction and management of bone complications in prostate cancer
Preventing and mitigating skeletal-related events in breast cancer